Sulpiride, a selective antagonist for adenylate cyclase-independent dopamine receptors, was administrated to 25 patients with blepharospasm and oromandibular dystonia(Meige's syndrome). Of the 25, 7 patients (28%) exhibited marked and lasting improvement with sulpiride and 12 patients (48%) showed mild or transient improvement. This favorable therapeutic response to sulpiride suggests that striatal glutamate underactivity may play a role in the pathophysiology of Meige's syndrome as a primary or secondary defect.
Adult ; Aged ; Basal Ganglia Diseases/*drug therapy ; Corpus Striatum/metabolism ; Dopamine/metabolism ; Female ; Glutamates/metabolism ; Glutamic Acid ; Human ; Male ; Meige Syndrome/*drug therapy/metabolism ; Middle Age ; Sulpiride/*therapeutic use